ANI Pharmaceuticals received FDA approval for the Abbreviated New Drug Application for Estradiol Tablets USP. ANI’s Estradiol Tablets USP are the generic version of the Reference Listed Drug Estrace. The current annual U.S. market for Estradiol Tablets USP is approximately $40.9M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANIP:
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
- ANI Pharmaceuticals management to meet virtually with Truist
- ANI Pharmaceuticals announces FDA approval and launch of Estradiol Gel
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
- ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference